Low infiltration of tumor-associated macrophages in high c-Myb-expressing breast tumors.
Adult
Aged
Aged, 80 and over
Antigens, CD
/ metabolism
Antigens, Differentiation, Myelomonocytic
/ metabolism
Breast
/ pathology
Breast Neoplasms
/ genetics
Cell Proliferation
Cohort Studies
Datasets as Topic
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ immunology
Humans
Kaplan-Meier Estimate
Macrophages
/ immunology
Middle Aged
Prognosis
Proto-Oncogene Proteins c-myb
/ metabolism
Receptors, Cell Surface
/ metabolism
Tumor Microenvironment
/ genetics
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 08 2019
12 08 2019
Historique:
received:
04
04
2019
accepted:
25
07
2019
entrez:
14
8
2019
pubmed:
14
8
2019
medline:
28
10
2020
Statut:
epublish
Résumé
Tumor-associated macrophages (TAMs) are prominent components of tumor stroma that promotes tumorigenesis. Many soluble factors participate in the deleterious cross-talk between TAMs and transformed cells; however mechanisms how tumors orchestrate their production remain relatively unexplored. c-Myb is a transcription factor recently described as a negative regulator of a specific immune signature involved in breast cancer (BC) metastasis. Here we studied whether c-Myb expression is associated with an increased presence of TAMs in human breast tumors. Tumors with high frequency of c-Myb-positive cells have lower density of CD68-positive macrophages. The negative association is reflected by inverse correlation between MYB and CD68/CD163 markers at the mRNA levels in evaluated cohorts of BC patients from public databases, which was found also within the molecular subtypes. In addition, we identified potential MYB-regulated TAMs recruiting factors that in combination with MYB and CD163 provided a valuable clinical multigene predictor for BC relapse. We propose that identified transcription program running in tumor cells with high MYB expression and preventing macrophage accumulation may open new venues towards TAMs targeting and BC therapy.
Identifiants
pubmed: 31406165
doi: 10.1038/s41598-019-48051-1
pii: 10.1038/s41598-019-48051-1
pmc: PMC6690941
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
CD163 antigen
0
CD68 antigen, human
0
MYB protein, human
0
Proto-Oncogene Proteins c-myb
0
Receptors, Cell Surface
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11634Références
Cancer Cell Int. 2015 Feb 07;15(1):17
pubmed: 25685069
Nature. 2005 Jul 28;436(7050):518-24
pubmed: 16049480
Nature. 2014 Nov 6;515(7525):130-3
pubmed: 25337873
Cancer Treat Rev. 2018 Nov;70:178-189
pubmed: 30227299
Nature. 2011 Jun 08;475(7355):222-5
pubmed: 21654748
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
J Hematol Oncol. 2017 Feb 28;10(1):58
pubmed: 28241846
Front Immunol. 2018 Nov 13;9:2629
pubmed: 30483271
Oncoimmunology. 2015 Nov 24;5(3):e1115177
pubmed: 27141367
Oncotarget. 2017 May 2;8(18):30576-30586
pubmed: 28427165
J Exp Med. 2001 Mar 19;193(6):727-40
pubmed: 11257139
Br J Cancer. 2017 Nov 21;117(11):1583-1591
pubmed: 29065107
Cancers (Basel). 2014 Aug 13;6(3):1670-90
pubmed: 25125485
Comput Math Methods Med. 2014;2014:813067
pubmed: 24639887
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):173-7
pubmed: 14734466
J Exp Clin Cancer Res. 2006 Sep;25(3):365-72
pubmed: 17167977
Histopathology. 2015 May;66(6):873-83
pubmed: 25387851
Oncogene. 2018 Feb 22;37(8):1020-1030
pubmed: 29084208
J Immunol Res. 2014;2014:149185
pubmed: 24901008
Cancer Immunol Immunother. 2008 Oct;57(10):1451-9
pubmed: 18297280
Breast Cancer Res Treat. 2006 Nov;100(2):229-35
pubmed: 16932852
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
J Exp Med. 2015 Jun 29;212(7):1043-59
pubmed: 26056232
J Natl Cancer Inst. 1994 Jan 19;86(2):120-6
pubmed: 8271294
Nat Rev Cancer. 2008 Jul;8(7):523-34
pubmed: 18574464
PLoS One. 2009 Aug 10;4(8):e6562
pubmed: 19668347
Blood. 1996 Apr 15;87(8):3336-43
pubmed: 8605350
Cancer Res. 2011 Nov 15;71(22):7029-37
pubmed: 21948968
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Mol Cancer. 2012 Mar 23;11:15
pubmed: 22439866
Oncogene. 2014 Jun 19;33(25):3217-24
pubmed: 23851506
Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):7265-70
pubmed: 21482760
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
J Cancer. 2019 Feb 23;10(6):1393-1397
pubmed: 31031849
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Breast Cancer Res. 2010;12(4):R55
pubmed: 20659323
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
J Pathol. 2012 May;227(1):17-28
pubmed: 22262122
J Clin Invest. 2004 Sep;114(5):623-33
pubmed: 15343380
Nat Commun. 2018 Jan 2;9(1):21
pubmed: 29295986
Expert Opin Biol Ther. 2008 Jun;8(6):713-7
pubmed: 18476782
Cancer Immunol Res. 2014 Aug;2(8):765-76
pubmed: 25005824
Breast Cancer Res Treat. 2012 Apr;132(3):781-91
pubmed: 21373875
Clin Cancer Res. 2000 Aug;6(8):3282-9
pubmed: 10955814
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
Breast Cancer Res. 2013 Nov 27;15(6):R113
pubmed: 24283570
PLoS One. 2013 Sep 16;8(9):e74250
pubmed: 24066126
Anticancer Res. 2015 Feb;35(2):865-74
pubmed: 25667468
Oncotarget. 2016 Aug 2;7(31):49349-49367
pubmed: 27283985
Nature. 2011 Apr 21;472(7343):303-4
pubmed: 21512566
Cancer Res. 2016 Jun 1;76(11):3166-78
pubmed: 27197153
Int J Cancer. 2008 Aug 15;123(4):780-6
pubmed: 18506688
Biochim Open. 2017 Jan 05;4:8-18
pubmed: 29450136
Eur J Surg Oncol. 1986 Sep;12(3):273-6
pubmed: 3758366
Breast Cancer Res Treat. 2014 Jan;143(2):403-9
pubmed: 24337596
Tumour Biol. 2016 Aug;37(8):10723-9
pubmed: 26873484
Endocr Relat Cancer. 2013 Oct 14;20(6):777-83
pubmed: 24016870
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
Onco Targets Ther. 2014 Aug 21;7:1475-80
pubmed: 25187727
PLoS One. 2010 Oct 07;5(10):e13073
pubmed: 20949095
Front Immunol. 2014 Oct 07;5:489
pubmed: 25339957
J Transl Med. 2011 Oct 17;9:177
pubmed: 22005011
BMC Cancer. 2012 Jul 23;12:306
pubmed: 22824040
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Cancer Res. 2004 Aug 1;64(15):5378-84
pubmed: 15289345
Virchows Arch. 2002 Jun;440(6):583-8
pubmed: 12070596
Br J Cancer. 2006 Aug 7;95(3):272-81
pubmed: 16832418
Clin Cancer Res. 2009 Feb 1;15(3):778-87
pubmed: 19188147
Mediators Inflamm. 2016;2016:6058147
pubmed: 26966341
Sci Rep. 2018 Jan 10;8(1):256
pubmed: 29321503
Mod Pathol. 2016 Aug;29(8):810-23
pubmed: 27125354
Breast Cancer Res. 2015 Aug 05;17:101
pubmed: 26243145
Eur J Immunol. 2014 Aug;44(8):2247-62
pubmed: 24796276
Oncotarget. 2018 May 1;9(33):23126-23148
pubmed: 29796177